Blueprint Medicines Corporation

NasdaqGS:BPMC Stock Report

Market Cap: US$5.8b

Blueprint Medicines Management

Management criteria checks 3/4

Blueprint Medicines' CEO is Kate Haviland, appointed in Apr 2022, has a tenure of 1.92 years. total yearly compensation is $6.22M, comprised of 11.3% salary and 88.7% bonuses, including company stock and options. directly owns 0.098% of the company’s shares, worth $5.68M. The average tenure of the management team and the board of directors is 3.5 years and 8.9 years respectively.

Key information

Kate Haviland

Chief executive officer

US$6.2m

Total compensation

CEO salary percentage11.3%
CEO tenure1.9yrs
CEO ownership0.1%
Management average tenure3.5yrs
Board average tenure8.9yrs

Recent management updates

Recent updates

Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)

Feb 20

Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Jan 08
Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%

Dec 18
Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%

Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?

Nov 20
Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?

Jul 26
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?

Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

Apr 16
Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 09
Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Dec 12
Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Nov 07
Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal

Sep 15

Blueprint to seek label expansion for systemic mastocytosis therapy after trial win

Aug 17

Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance

Aug 02

Blueprint to sell Ayvakit royalty for $250M upfront; Gavreto royalty for $175M upfront

Jun 30

Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook

Feb 17
Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook

Here's Why We're Not Too Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Situation

Nov 10
Here's Why We're Not Too Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Situation

Calculating The Intrinsic Value Of Blueprint Medicines Corporation (NASDAQ:BPMC)

Oct 15
Calculating The Intrinsic Value Of Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines: What Now

Jun 21

CEO Compensation Analysis

How has Kate Haviland's remuneration changed compared to Blueprint Medicines's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$507m

Sep 30 2023n/an/a

-US$555m

Jun 30 2023n/an/a

-US$554m

Mar 31 2023n/an/a

-US$581m

Dec 31 2022US$6mUS$701k

-US$558m

Sep 30 2022n/an/a

-US$718m

Jun 30 2022n/an/a

-US$702m

Mar 31 2022n/an/a

-US$650m

Dec 31 2021US$4mUS$501k

-US$644m

Sep 30 2021n/an/a

-US$411m

Jun 30 2021n/an/a

US$340m

Mar 31 2021n/an/a

US$325m

Dec 31 2020US$2mUS$461k

US$314m

Sep 30 2020n/an/a

US$333m

Jun 30 2020n/an/a

-US$395m

Mar 31 2020n/an/a

-US$371m

Dec 31 2019US$3mUS$432k

-US$348m

Sep 30 2019n/an/a

-US$362m

Jun 30 2019n/an/a

-US$340m

Mar 31 2019n/an/a

-US$267m

Dec 31 2018US$3mUS$393k

-US$237m

Sep 30 2018n/an/a

-US$205m

Jun 30 2018n/an/a

-US$170m

Mar 31 2018n/an/a

-US$177m

Dec 31 2017US$1mUS$353k

-US$148m

Compensation vs Market: Kate's total compensation ($USD6.22M) is about average for companies of similar size in the US market ($USD7.72M).

Compensation vs Earnings: Kate's compensation has increased whilst the company is unprofitable.


CEO

Kate Haviland (47 yo)

1.9yrs

Tenure

US$6,217,694

Compensation

Ms. Kathryn Haviland, also known as Kate, is Director of Bicara Therapeutic, Inc. from October 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serves as President, Chie...


Leadership Team

NamePositionTenureCompensationOwnership
Kathryn Haviland
President1.9yrsUS$6.22m0.098%
$ 5.7m
Alexis Borisy
Co-Founder & Directorno dataUS$323.52k0.11%
$ 6.6m
Michael Landsittel
Chief Financial Officer8.1yrsUS$2.36m0.026%
$ 1.5m
Christina Rossi
Chief Operating Officer1.9yrsUS$2.77m0.045%
$ 2.6m
Tracey McCain
Executive VP7.5yrsUS$2.34m0.048%
$ 2.8m
Fouad Namouni
President of Research & Development3.5yrsUS$2.81m0.045%
$ 2.6m
Ariel Hurley
Senior VP1.2yrsno data0.024%
$ 1.4m
Christopher Murray
Senior VP of Technical Operations and Chief Technical Operations & Quality Officer6.4yrsUS$3.79m0.055%
$ 3.2m
Percy Carter
Chief Scientific Officer2.8yrsUS$4.59m0.079%
$ 4.6m
Jenna Cohen
Senior Director & Head of Investor Relationsno datano datano data
Debra Durso-Bumpus
Chief People Officer4.1yrsno data0.043%
$ 2.5m
Julian Baker
Senior Vice President of Corporate Affairsno datano datano data

3.5yrs

Average Tenure

52yo

Average Age

Experienced Management: BPMC's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kathryn Haviland
President1.9yrsUS$6.22m0.098%
$ 5.7m
Alexis Borisy
Co-Founder & Director12.9yrsUS$323.52k0.11%
$ 6.6m
George Demetri
Member of Scientific Advisory Board11.8yrsUS$333.38kno data
Lynn Seely
Lead Independent Director7.9yrsUS$373.59k0.014%
$ 797.5k
Charles Sawyers
Member of Scientific Advisory Boardno datano datano data
Brian Druker
Member of Scientific Advisory Boardno datano datano data
Nicholas Lydon
Member of Scientific Advisory Board & Independent Director12.9yrsUS$348.45k0.087%
$ 5.0m
Lonnel Coats
Independent Director8.1yrsUS$346.39k0.014%
$ 797.5k
Scott Lowe
Member of Scientific Advisory Boardno datano datano data
Giulio Draetta
Member of Scientific Advisory Boardno datano datano data
Daniella Beckman
Independent Director2.3yrsUS$326.51k0.0061%
$ 354.1k
Jeffrey Albers
Chairman9.7yrsUS$1.59m0.24%
$ 14.1m

8.9yrs

Average Tenure

61yo

Average Age

Experienced Board: BPMC's board of directors are considered experienced (8.9 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.